Treatment with ustekinumab leads to significant reductions in severe flares in systemic lupus erythematosus (SLE) patients with active disease, 1-year data from a Phase 2 trial shows. Biomarker analyses of the same data also provided clues about how ustekinumab works in SLE. The data were presented at the…
Gazyva (obinutuzumab) in combination with standard-of-care agents significantly increases the percentage of patients with proliferative lupus nephritis achieving complete or partial renal response, top-line data from a Phase 2 trial show. Gazyva is a monoclonal antibody that has been designed to bind CD20,…
KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus erythematosus (SLE), preliminary Phase 1b data show. The findings were presented at the European League Against Rheumatism (EULAR) 2019 Annual Meeting in Geneva, Switzerland, in a poster titled, “…
These days, more than ever, we need community. As a culture, we are experiencing higher levels of stress, greater incidence of isolation, and an increase in the prevalence of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and others. Slowly, we are starting…
Only a select few are invited to ring the Nasdaq stock exchange bell. The Lupus Foundation of America (LFA) was among them, taking part in closing ceremonies earlier this month. The foundation’s goal in those June 7 ceremonies was to raise awareness of the unpredictable and often-misunderstood disease and…
Certain rare gene mutations, previously ignored, appear to contribute substantially to the development of lupus, new research found, pointing to the potential for targeted therapies for the condition. The study, “Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus,” was published in …
In studying how mycophenolate mofetil treatment affects immune cells and blood markers in people with systemic lupus erythematosus (SLE), researchers uncovered an immune pathway that may explain why is lupus suppressed by this medication. Their findings might…
Platelet-bound C4d (PC4d), one of Exagen‘s patented biomarkers, may be used along with other available biomarkers to estimate the risk of thrombosis — the formation of blood clots — among people with systemic lupus erythematosus (SLE), a study shows. The study, “Platelet-bound C4d, low C3…
Tofacitinib tablets, a medicine approved to treat rheumatoid and psoriatic arthritis, may work for lessening signs and symptoms of arthritis and skin rash in people with systemic lupus erythematosus (SLE), a…
Michigan Medicine researchers were granted up to $10.2 million by the Autoimmunity Centers of Excellence (ACE) to develop new projects seeking treatments for autoimmune diseases including lupus. In particular, the team from the University of Michigan’s academic medical center is focused on exploring the relationship between molecular targets…